Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Eli Lilly and Company

19 clinical trials · 19 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Eli Lilly and Company

RECRUITINGPhase 1NCT06238479

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The...

Sponsor: Eli Lilly and CompanyEnrolling: 49020 locations
Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid Tumor+11
RECRUITINGPhase 1NCT06586515

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in...

Sponsor: Eli Lilly and CompanyEnrolling: 63020 locations
Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal Cancer
RECRUITINGPhase 1NCT06297590

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much...

Sponsor: Eli Lilly and CompanyEnrolling: 4810 locations
Alzheimer Disease
RECRUITINGPhase 3NCT07142954

Epidemiology and Biomarker Study in Alzheimer's Disease

Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.

Sponsor: Eli Lilly and CompanyEnrolling: 34003 locations
Alzheimer Disease
RECRUITINGPhase 3NCT05508789

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is...

Sponsor: Eli Lilly and CompanyEnrolling: 150020 locations
Alzheimer DiseaseDementiaBrain Diseases+6
RECRUITINGPhase 1 / Phase 2NCT05768139

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With...

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478...

Sponsor: Eli Lilly and CompanyEnrolling: 72020 locations
Breast CancerSolid Tumors, Adult
RECRUITINGPhase 1NCT07258849

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA)....

Sponsor: Eli Lilly and CompanyEnrolling: 1349 locations
HealthyRheumatoid Arthritis (RA)
RECRUITINGPhase 2NCT05848258

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).

Sponsor: Eli Lilly and CompanyEnrolling: 38020 locations
Rheumatoid Arthritis
RECRUITINGPhase 3NCT05509777

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to...

Sponsor: Eli Lilly and CompanyEnrolling: 9020 locations
Crohn's Disease
RECRUITINGPhase 4NCT06864026

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active...

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA...

Sponsor: Eli Lilly and CompanyEnrolling: 20020 locations
Psoriatic ArthritisOverweight or Obesity
RECRUITINGPhase 3NCT06972459

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related...

The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other...

Sponsor: Eli Lilly and CompanyEnrolling: 60020 locations
ObesityOverweight
RECRUITINGPhase 1NCT06945406

A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes

The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes....

Sponsor: Eli Lilly and CompanyEnrolling: 1241 location
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
RECRUITINGPhase 3NCT07222332

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1...

The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last...

Sponsor: Eli Lilly and CompanyEnrolling: 30020 locations
Diabetes Mellitus, Type 1
RECRUITINGPhase 1NCT06280703

A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)

The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it. At a later...

Sponsor: Eli Lilly and CompanyEnrolling: 1181 location
HealthyType 1 Diabetes Mellitus
RECRUITINGPhase 3NCT07222137

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the...

Sponsor: Eli Lilly and CompanyEnrolling: 15020 locations
Diabetes Mellitus, Type 1
RECRUITINGPhase 3NCT07232719

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65...

Sponsor: Eli Lilly and CompanyEnrolling: 25020 locations
ObesityOverweight
RECRUITINGPhase 3NCT06672939

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

The main purpose of this study, performed under Master Protocol J4M-MC-PWMP, is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus...

Sponsor: Eli Lilly and CompanyEnrolling: 12520 locations
ObesityOverweight
RECRUITINGPhase 3NCT07165028

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease...

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk...

Sponsor: Eli Lilly and CompanyEnrolling: 450020 locations
Metabolic Dysfunction-Associated Steatotic Liver Disease
RECRUITINGPhase 2NCT07269210

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe...

Sponsor: Eli Lilly and CompanyEnrolling: 6020 locations
Severe Hypertriglyceridemia